Andreas Trojan

2.5k total citations
64 papers, 1.8k citations indexed

About

Andreas Trojan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Andreas Trojan has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 14 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in Andreas Trojan's work include Immunotherapy and Immune Responses (11 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Andreas Trojan is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (10 papers). Andreas Trojan collaborates with scholars based in Switzerland, Germany and United States. Andreas Trojan's co-authors include Anand Rajeswaran, Bernard Burnand, Mathias Witzens‐Harig, John G. Gribben, Rolf A. Stahel, Mirjana Urosevic, Reinhard Dummer, John W. Donovan, Marco Ladetto and Joachim L. Schultze and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Andreas Trojan

62 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Trojan Switzerland	22	741	567	339	295	215	64	1.8k
Elísabeth Pérez-Ruiz Spain	20	1.0k 1.4×	600 1.1×	574 1.7×	339 1.1×	148 0.7×	80	1.9k
Sang Won Shin South Korea	26	1.2k 1.7×	176 0.3×	551 1.6×	950 3.2×	253 1.2×	122	2.5k
Frank Gieseler Germany	28	1.3k 1.7×	387 0.7×	1.1k 3.1×	331 1.1×	203 0.9×	97	2.6k
Melinda S. Merchant United States	25	1.3k 1.7×	964 1.7×	850 2.5×	730 2.5×	102 0.5×	56	2.8k
Ju Yang China	17	761 1.0×	499 0.9×	510 1.5×	248 0.8×	111 0.5×	62	1.6k
Arthur G. Pratt United Kingdom	25	385 0.5×	575 1.0×	439 1.3×	121 0.4×	231 1.1×	94	2.2k
Inês Pires da Silva Australia	25	1.0k 1.4×	808 1.4×	539 1.6×	247 0.8×	141 0.7×	106	2.0k
Bruno Nervi Chile	17	953 1.3×	336 0.6×	491 1.4×	424 1.4×	698 3.2×	53	2.0k
Diane E. Cole United States	24	912 1.2×	251 0.4×	661 1.9×	338 1.1×	95 0.4×	55	2.2k

Countries citing papers authored by Andreas Trojan

Since Specialization

Citations

This map shows the geographic impact of Andreas Trojan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Trojan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Trojan more than expected).

Fields of papers citing papers by Andreas Trojan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Trojan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Trojan. The network helps show where Andreas Trojan may publish in the future.

Co-authorship network of co-authors of Andreas Trojan

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Trojan. A scholar is included among the top collaborators of Andreas Trojan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Trojan. Andreas Trojan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rothgiesser, Karin, W. Schönfeld, Roger von Moos, et al.. (2025). Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 25(6). 583–588. 1 indexed citations

Papassotiropoulos, Bärbel, Constanze Elfgen, Konstantin J. Dedes, et al.. (2022). Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy. Scientific Reports. 12(1). 91–91. 12 indexed citations

Mueller, Andreas, Qiyu Li, Beat Thuerlimann, et al.. (2022). Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]. Journal of Geriatric Oncology. 14(1). 101372–101372. 1 indexed citations

Trojan, Andreas, Christoph Thomssen, Achim Rody, et al.. (2021). The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial. Journal of Medical Internet Research. 23(8). e29271–e29271. 8 indexed citations

Trojan, Andreas, et al.. (2021). Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study. JMIR Cancer. 7(1). e26950–e26950. 8 indexed citations

Trojan, Andreas, et al.. (2020). Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. Breast Cancer Research and Treatment. 183(2). 311–319. 10 indexed citations

Wuerstlein, Rachel, Ronald Kates, Oleg Gluz, et al.. (2019). Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Research and Treatment. 175(2). 389–399. 22 indexed citations

Rochlitz, Christoph, Roger von Moos, Jürg Bernhard, et al.. (2016). SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC Cancer. 16(1). 780–780. 40 indexed citations

Egbring, Marco, Małgorzata Roos, Michael Dietrich, et al.. (2016). A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial. Journal of Medical Internet Research. 18(9). e238–e238. 73 indexed citations

10.

Smolle, Elisabeth, Andreas Trojan, Stephen J. Schuster, & Johannes Haybaeck. (2015). Progressive multifocal leukoencephalopathy--a case report and review of the literature.. PubMed. 28(5). 941–8. 9 indexed citations

11.

Varga, Zsuzsanna, Hans‐Peter Sinn, A. von Hochstetter, et al.. (2013). Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. PLoS ONE. 8(3). e58483–e58483. 47 indexed citations

12.

Krzemieniecki, Krzysztof, P. Sevelda, Frans Erdkamp, et al.. (2013). Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Supportive Care in Cancer. 22(3). 667–677. 25 indexed citations

13.

Trojan, Andreas, et al.. (2012). The Discriminatory Value of <i>CYP2D6</i> Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer. Breast Care. 7(1). 25–31. 5 indexed citations

14.

Probst, Sebastian, Anne Arber, Andreas Trojan, & Sara Faithfull. (2012). Caring for a loved one with a malignant fungating wound. Supportive Care in Cancer. 20(12). 3065–3070. 25 indexed citations

15.

Rajeswaran, Anand, et al.. (2007). Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer. 59(1). 1–11. 176 indexed citations

16.

Trojan, Andreas, Rajendran Rajeswaran, Michael Montemurro, Margot Mütsch, & Robert Steffen. (2007). Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination. Journal of Clinical Virology. 40(1). 80–83. 5 indexed citations

17.

Trojan, Andreas, et al.. (2003). Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR.. Journal of Immunotherapy. 26(1). 41–46. 13 indexed citations

18.

Trojan, Andreas, et al.. (2002). Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma. Annals of Hematology. 81(9). 535–537. 17 indexed citations

19.

Urosevic, Mirjana, Michael Kurrer, Jivko Kamarashev, et al.. (2001). Human Leukocyte Antigen G Up-Regulation in Lung Cancer Associates with High-Grade Histology, Human Leukocyte Antigen Class I Loss and Interleukin-10 Production. American Journal Of Pathology. 159(3). 817–824. 177 indexed citations

20.

Trojan, Andreas, Joachim L. Schultze, Mathias Witzens‐Harig, et al.. (2000). Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nature Medicine. 6(6). 667–672. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact